Drug Database
Back to search

France· FR:65772900

OPTIRAY 350 (350 mg I/mL), solution injectable en flacon

A ioversol product containing ioversol, registered in France by GUERBET. The same ATC class is registered in 14 of our 19 countries.

ATC V08AB07

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedOPTIRAY 350 (350 mg I/mL), solution i…ATCV08AB07REGISTER NO.FR:65772900PACKS LISTED7CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about ioversolAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Ioversol is registered in 14 of 19 countries.

Countries holding a registration under ATC V08AB07 (ioversol), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 7 of them publish a price we can compare per daily dose
Search ioversol products by name

Ioversol · ATC V08AB07

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Ireland
  • Japan
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
IOVERSOL
Manufacturer
GUERBET
Country
France (FR)
ATC code
V08AB07
ATC class
Ioversol
Reimbursed
No
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 7

  • cip13
    3400930282090
    1 flacon(s) en verre de 500 ml
  • cip13
    3400933276645
    1 flacon(s) en verre de 50 ml
  • cip13
    3400933276874
    1 flacon(s) en verre de 100 ml
  • cip13
    3400933276935
    1 flacon(s) en verre de 200 ml
  • cip13
    3400933277017
    1 flacon(s) en verre de 50 ml - avec seringue(s) - polypropylène - avec matériel de perfusion
  • cip13
    3400956034185
    25 flacon(s) en verre de 50 ml
  • cip13
    3400956034246
    10 flacon(s) en verre de 100 ml

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

188 interactions on record for ioversol.

Graded by severity as the source publishes them — 94 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check ioversol against other medicinesHow interaction checks work

Ioversol · interactions on record

188 records

  • 94 severe
  • 55 moderate
  • 39 info

Most severe, free to view

  • NeomycinA07AA01severe
  • StreptomycinA07AA04severe
  • Polymyxin BA07AA05severe
  • Amphotericin BA07AA07severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ioversol in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ioversol products

Authorised across Europe · EMA

The same active substance is authorised in 21 EEA countries. Names it is sold under:

  • Austria · Optiray
  • Belgium · Optiject, Optiray
  • Czechia · Optiray
  • Germany · Optiray
  • Denmark · Optiray
  • Spain · Optiray, Optiray Ultraject
  • Finland · Optiray
  • United Kingdom (Northern Ireland) · Optiray
  • Greece · Optiray
  • Croatia · Optiray
  • Hungary · Optiray
  • Ireland · Optiray
  • Italy · Optiray
  • Luxembourg · Optiject, Optiray
  • Netherlands · Optiray
  • Norway · Optiray
  • Poland · Optiray
  • Portugal · Optiray
  • Romania · Optiray
  • Sweden · Optiray
  • Slovakia · Optiray

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/bbe04155-5fdc-47af-b803-0e8804b7f0d3
GET /v1/drugs/bbe04155-5fdc-47af-b803-0e8804b7f0d3?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "65772900",
  "date_amm": "1990-02-05",
  "type_amm": "Procédure nationale",
  "numero_ue": null,
  "substance": "IOVERSOL",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "solution injectable",
  "voies_administration": "intraartérielle;intraveineuse",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}
API referenceMCP serverPlans

See everything about ioversol.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console